Development of a neonatal adverse event severity scale through a Delphi consensus approach

Author:

Salaets Thomas,Turner Mark AORCID,Short Mary,Ward Robert M,Hokuto Isamu,Ariagno Ronald L,Klein Agnes,Beauman Sandra,Wade Kelly,Thomson Merran,Roberts Eve,Harrison Judy,Quinn Theresa,Baer Gerri,Davis Jonathan,Allegaert KarelORCID

Abstract

BackgroundAssessment of the seriousness, expectedness and causality are necessary for any adverse event (AE) in a clinical trial. In addition, assessing AE severity helps determine the importance of the AE in the clinical setting. Standardisation of AE severity criteria could make safety information more reliable and comparable across trials. Although standardised AE severity scales have been developed in other research fields, they are not suitable for use in neonates. The development of an AE severity scale to facilitate the conduct and interpretation of neonatal clinical trials is therefore urgently needed.MethodsA stepwise consensus process was undertaken within the International Neonatal Consortium (INC) with input from all relevant stakeholders. The consensus process included several rounds of surveys (based on a Delphi approach), face-to-face meetings and a pilot validation.ResultsNeonatal AE severity was classified by five grades (mild, moderate, severe, life threatening or death). AE severity in neonates was defined by the effect of the AE on age appropriate behaviour, basal physiological functions and care changes in response to the AE. Pilot validation of the generic criteria revealed κ=0.23 and guided further refinement. This generic scale was applied to 35 typical and common neonatal AEs resulting in the INC neonatal AE severity scale (NAESS) V.1.0, which is now publicly available.DiscussionThe INC NAESS is an ongoing effort that will be continuously updated. Future perspectives include further validation and the development of a training module for users.

Funder

Agentschap voor Innovatie door Wetenschap en Technologie

US Food and Drug Administration

Publisher

BMJ

Subject

Pediatrics, Perinatology and Child Health

Reference28 articles.

1. Abraham J . International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use. In: Handbook of transnational economic governance regimes. Brill, 2009: 1041–54.

2. Center for Drug Evaluation and Research . Investigational New Drug (IND) Application - Final Rule: Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans. Available: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm226358.htm [Accessed 1 Dec 2018].

3. Center for Devices and Radiological Health . Medical Device Databases - Code of Federal Regulations - Title 21 - Food and Drugs. Available: https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Databases/ucm135680.htm [Accessed 1 Dec 2018].

4. Stoll BJ , Hansen NI , Bell EF , et al . Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA 2015;314.doi:10.1001/jama.2015.10244

5. FDA . Guidance to industry and Investigaors: safety reporting requirements for IND and BA/BE. Available: https://www.fda.gov/downloads/Drugs/Guidances/UCM227351.pdf

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3